GSC
PLX icon

Ground Swell Capital’s Protalix BioTherapeutics PLX Stock Holding History

Ground Swell Capital’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-62,234
Closed -$72.8K – 243
2024
Q2 		$72.8K Buy
+62,234
New +$73.5K 0.06% 96
2021
Q2 		– Sell
-14,684
Closed -$65K – 137
2021
Q1 		$65K Buy
+14,684
New +$68.4K 0.21% 82

Other funds holding PLX

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SWP
Stratos Wealth Partners Beachwood, Ohio $8.8B AUM 21.82% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
OGF
Orin Green Financial San Diego, California $271M AUM 20.78% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $18.5B AUM 23.32% 1-Year Est. Return

Ground Swell Capital's PLX Position: Q3 2024 in Review

Ground Swell Capital sold out of Protalix BioTherapeutics (PLX) in Q3 2024, closing a stake of 62,234 shares — an estimated $72.8K sold.

Ground Swell Capital first reported a position in PLX in Q1 2021 and held it in 2 quarters. The position peaked at $72.8K in Q2 2024. 45 funds tracked by Wall St. Rank hold PLX as of Q3 2024.

  • Ground Swell Capital reported no remaining Protalix BioTherapeutics position as of Q3 2024 after selling out during the quarter.
  • Ground Swell Capital sold 62,234 Protalix BioTherapeutics shares in Q3 2024, an estimated $72.8K.
  • Ground Swell Capital first reported a position in Protalix BioTherapeutics in Q1 2021 and held it in 2 quarters.
  • Ground Swell Capital's Protalix BioTherapeutics position peaked at $72.8K in Q2 2024.
  • 45 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2024.

Based on Ground Swell Capital's 13F filing for Q3 2024, filed 29 Oct 2024.